Which drug is associated with increased lipoprotein levels?

Which drug is associated with increased lipoprotein levels?

• A. Furosemide (Lasix)
• B. Hydrochlorothiazide (HCTZ)
• C. Spironolactone (Aldactone)
• D. Triamterene (Dyrenium)

Answer: (B)

Hydrochlorothiazide (HCTZ) is a thiazide diuretic that has been associated with increased levels of lipoproteins, particularly low-density lipoprotein (LDL) cholesterol and triglycerides. While thiazide diuretics are primarily used for their antihypertensive effects by promoting diuresis and reducing blood volume, they can also lead to metabolic changes that might elevate lipid levels. This phenomenon may be attributed to several potential mechanisms, including alterations in lipid metabolism and the impact on insulin sensitivity. It's important for healthcare providers to monitor lipid profiles in patients who are prescribed HCTZ, especially if they have a history of hyperlipidemia or are at risk for cardiovascular disease. On the other hand, the other medications listed—furosemide, spironolactone, and triamterene—do not have a significant association with increased lipoprotein levels. Furosemide is a loop diuretic that primarily affects renal function and fluid balance, while spironolactone and triamterene are potassium-sparing diuretics that do not influence lipid levels in a clinically significant way. Therefore, hydrochlorothiazide stands out as having the most noteworthy impact on increasing

Hydrochlorothiazide (HCTZ) is a thiazide diuretic that has been associated with increased levels of lipoproteins, particularly low-density lipoprotein (LDL) cholesterol and triglycerides. While thiazide diuretics are primarily used for their antihypertensive effects by promoting diuresis and reducing blood volume, they can also lead to metabolic changes that might elevate lipid levels.

This phenomenon may be attributed to several potential mechanisms, including alterations in lipid metabolism and the impact on insulin sensitivity. It's important for healthcare providers to monitor lipid profiles in patients who are prescribed HCTZ, especially if they have a history of hyperlipidemia or are at risk for cardiovascular disease.

On the other hand, the other medications listed—furosemide, spironolactone, and triamterene—do not have a significant association with increased lipoprotein levels. Furosemide is a loop diuretic that primarily affects renal function and fluid balance, while spironolactone and triamterene are potassium-sparing diuretics that do not influence lipid levels in a clinically significant way. Therefore, hydrochlorothiazide stands out as having the most noteworthy impact on increasing